KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.

Kirk U Knowlton, Ann Marie Navar, Jeffrey L Anderson, Alan S Brown, Joseph B Muhlestein, Kelly Kleeman, Samiha Sarwat, Cheryl A Abbas, Mary Ann Ramirez, Cindy L Grines, Wael S Abo-Auda, Nihar R Desai

J Am Heart Assoc 15(10) e043655

PMID42132192
PMCIDPMC13279551
DOI10.1161/JAHA.125.043655
发表日期2026-05-14
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: The low-density lipoprotein cholesterol (LDL-C)-lowering effect of inclisiran, a proprotein convertase subtilisin/kexin type 9-targeting small interfering RNA, has not been established in patients with recent acute coronary syndrome. METHODS: VICTORION-INCEPTION, a 330-day, phase 3b, open-label, multicenter trial, designed to mimic clinical practice, randomized 400 eligible participants (discharged following acute coronary syndrome ≤5 weeks of screening, with LDL-C ≥70 mg/dL [or non-high-density lipoprotein cholesterol ≥100 mg/dL], receiving statin therapy or statin intolerant) 1:1 to inclisiran sodium 300 mg (284 mg inclisiran equivalent; Days 0, 90, 270) + usual care, or usual care (clinician-directed LDL-C management). Coprimary end points at Day 330 were LDL-C <70 mg/dL attainment and LDL-C percentage change from baseline. RESULTS: At Day 90, inclisiran + usual care led to greater LDL-C goal attainment and lowering versus usual care (<70 mg/dL: 74.6% versus 26.6%, odds ratio [OR], 10.84 [97.5% CI, 6.13-19.16]; <55 mg/dL: 63.2% versus 8.5%, OR, 26.58 [95% CI, 14.14-49.98]; percentage change from baseline: -48.9% versus 2.2%); this was sustained to Day 330 (<70 mg/dL: 66.7% versus 28.1%, OR, 5.42 [97.5% CI, 3.29-8.91], P<0.001; <55 mg/dL: 54.2% versus 13.6%, OR, 8.24 [95% CI, 4.97-13.65]; percentage change: -46.9% difference [97.5% CI, -55.4 to -38.5]; P<0.001). Participants with ≥1 adverse events were comparable (inclisiran + usual care, 58.6%; usual care, 53.3%). CONCLUSIONS: VICTORION-INCEPTION was the first inclisiran trial in participants with recent acute coronary syndrome. Early inclisiran initiation with usual care resulted in rapid, sustained attainment of guideline-directed LDL-C goals and was well tolerated. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT04873934.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. VICTORION‐INCEPTION study design and participant disposition. The study design ( A ) and participant disposition ( B ) of VICTORION‐INCEPTION. *Most frequent reasons (occurring in >2.5% of screened individuals) that individuals did not meet eligibility criteria; individuals may have failed to meet ≥1 eligibility criteria. † Further details as to the reason for loss to follow‐up were not captured in the clinical database. ‡ One participant remains with missing disposition information due to site being lost to follow‐up. ACS indicates acute coronary syndrome; EOS, end of study; HDL‐C, high‐density lipoprotein cholesterol; and LDL‐C, low‐density lipoprotein cholesterol.
非 KM Figure
Figure 2Figure 2. Attainment of LDL‐C < 70 mg/dL and percentage change in LDL‐C from baseline (coprimary end points). The proportion of participants achieving LDL‐C < 70 mg/dL ( A ) and LS mean percentage change from baseline in LDL‐C ( B ) and at each postbaseline visit. Data were analyzed in the full analysis set. For the proportion of participants achieving LDL‐C <70 mg/dL, percentages are based on the total number of participants in each arm. The primary analysis time point for each coprimary end point was Day 330 (EOS) and is indicated by yellow shading. Baseline refers to the last measurements available before or on study start date. * Nominal P values for Day 90 and Day 270 were <0.001. BL indicates baseline; EOS, end of study; LDL‐C, low‐density lipoprotein cholesterol; LS, least squares; and OR, odds ratio.
非 KM Figure
Figure 3Figure 3. The proportion of participants achieving prespecified and post hoc LDL‐C goals. The proportion of participants achieving LDL‐C < 100 mg/dL ( A ), LDL‐C <55 mg/dL ( B ), LDL‐C <40 mg/dL ( C ), and a ≥50% LDL‐C reduction from baseline ( D ). Data were analyzed in the full analysis set. Percentages are based on the total number of participants in each arm, with the exception of LDL‐C <100 mg/dL, which only includes participants with LDL‐C ≥100 mg/dL at baseline (inclisiran + usual care, n=62; usual care, n=52). Baseline refers to the last measurements available before or on study start date. All nominal P values were <0.001 except LDL‐C <100 mg/dL at Day 270 ( P =0.005). EOS indicates end of study; LDL‐C, low‐density lipoprotein cholesterol; and OR, odds ratio.
非 KM Figure
Figure 4Figure 4. Concomitant LLT at baseline and Day 330. Data were analyzed in the safety set. Baseline data reflect medications that were being taken at the start of study treatment. Day 330 data reflect medications that were being taken on the study date. Percentages are based on n (the number of participants with nonmissing visit date). * Monotherapy excludes concomitant use of ezetimibe, anti‐PCSK9 mAbs, or bempedoic acid. † Combination therapy includes any combination with ezetimibe, anti‐PCSK9 mAbs, and bempedoic acid, on the respective study date. ‡ Excluding concomitant use of any other LLT (eg, fenofibrate, omega‐3 fatty acid, fish oil). anti‐PCSK9 mAb indicates antiproprotein convertase subtilisin/kexin type 9 monoclonal antibody; LLT, lipid‐lowering therapy; and mAb, monoclonal antibody.
非 KM Figure